Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

  • AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis
    on May 21, 2019 at 12:00 pm

    MONTREAL , May 21, 2019 /CNW/ - AbbVie (ABBV), a global, research and development-driven biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NBIX), announced that ORILISSA™ (elagolix) 200 mg twice daily is now available. […]

  • Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life
    on May 20, 2019 at 12:00 pm

    SAN DIEGO, May 20, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), demonstrating the effect of involuntary movements (possible TD) on patient health-related quality of life. Results from the study showed that involuntary movements had a significant negative impact on a patient's health-related quality of life, with nearly 30% of patients with possible TD reporting moderate-to-extreme problems performing their usual activities, including work, housework and leisure activities. […]

  • Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting
    on May 16, 2019 at 8:01 pm

    SAN DIEGO, May 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD), an involuntary movement disorder. Neurocrine will also present new long-term data from the KINECT 4 Phase III, open-label study of INGREZZA® (valbenazine) capsules, highlighting the overall effect of treatment with INGREZZA on the abnormal movements associated with TD based on additional items from the Abnormal Involuntary Movement Scale (AIMS), including overall severity of abnormal movements, incapacitation due to abnormal movements and patient awareness of abnormal movements and distress level. […]

  • Trade Anxieties Return with a Vengeance
    on May 8, 2019 at 1:15 pm

    Trade Anxieties Return with a Vengeanc […]

  • Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019
    on May 7, 2019 at 8:01 pm

    SAN DIEGO, May 7, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2019 at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 14, 2019, in Las Vegas. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. […]

  • See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
    on May 7, 2019 at 12:02 pm

    Neurocrine Biosciences Inc NASDAQ/NGS:NBIXView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for NBIX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $4.77 billion over the last one-month into ETFs that hold NBIX are among the highest of the last year, but the rate of growth is slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report. […]

  • Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients
    on May 6, 2019 at 12:00 pm

    - Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on ... […]

  • Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
    on May 5, 2019 at 1:05 pm

    SAN DIEGO and CAMBRIDGE, Mass., May 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced Phase I trial results for VY-AADC from eight patients with Parkinson's disease who participated in the open-label trial to evaluate the safety and efficacy of VY-AADC and to further assess the posterior (i.e., from the back of the head) surgical delivery approach. Treatment with VY-AADC improved good ON time (ON time without troublesome dyskinesia) by 1.7 hours from baseline and reduced OFF time by 2.2 hours at 12 months from baseline in patients with Parkinson's disease. […]

  • Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations
    on May 5, 2019 at 1:00 pm

    SAN DIEGO, May 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced the presentation of a data analysis from two Phase III studies of opicapone, a novel, once-daily, oral, selective, peripherally-acting catechol-O-methyltransferase (COMT) inhibitor for the treatment of Parkinson's disease. The analysis found that treatment with opicapone 50 mg, added to levodopa, resulted in a significant and sustained increase in ON time without troublesome dyskinesia1, in Parkinson's disease patients with motor fluctuations. The analysis, which included data from more than 900 patients in the double-blind, placebo-controlled Phase III BIPARK-1 and BIPARK-2 studies, was highlighted as an oral session at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia. […]

  • Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT
    on May 3, 2019 at 3:54 am

    Q1 2019 Neurocrine Biosciences Inc Earnings Ca […]

2 hours ago

Alignmt LLC

No business plan can succeed with a flawed business model. buff.ly/2qhTkRY

#alignmentmap #corporatefinance #keyperformanceindicators #mergersandacquisitions #investorrelations
... See MoreSee Less

View on Facebook

2 hours ago

Alignmt LLC

It’s an exercise, which means it takes repetition. The more you try it, the better you get at it. The more skilled you become seeing things for what they are, the more perception will work for you rather than against you. buff.ly/2qhTkRY

#alignmentmap
... See MoreSee Less

View on Facebook

17 hours ago

Alignmt LLC

Organizing your business will help optimize efficiency in all functional areas, including business development, finance, operations, human resources, legal, IT and more. buff.ly/2qhTkRY

#alignmentmap #corporatefinance #keyperformanceindicators #mergersandacquisitions #investorrelations
... See MoreSee Less

View on Facebook

23 hours ago

Alignmt LLC

"Don't get so hung up on revenue." True story, a client actually said this to me once. I asked: "Do you say the same thing to investors?" There is no better money than revenue and it takes disciplined financial management to make the most of it. buff.ly/2qhTkRY

#alignmentmap #corporatefinance #mergersandacquisitions #investorrelations
... See MoreSee Less

View on Facebook

5 days ago

Alignmt LLC

Every company needs disciplined financial management to ensure its long-term viability in every respect. How precisely are you tracking key performance indicators? buff.ly/2AnLw8v

#keyperformanceindicators #alignmentmap #mergersandacquisitions
... See MoreSee Less

View on Facebook

5 days ago

Alignmt LLC

Who knew finance was so critical to success? buff.ly/2AnLw8v

#keyperformanceindicator #alignmentmap
... See MoreSee Less

View on Facebook

5 days ago

Alignmt LLC

Many companies lack the requisite Corporate finance expertise in-house to achieve important goals, while outsourcing often enables them to reach the next level of productivity In a cost effective, low risk manner.

#mergersandacquisitions #alignmentmap
... See MoreSee Less

View on Facebook

Want to maximize your business valuation? First things first when thinking about selling. https://t.co/5eZf2JKfts

Load More...

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130

+1 (858) 617-7600

www.neurocrine.com

May 2019
S M T W T F S
« Apr    
 1234
567891011
12131415161718
19202122232425
262728293031  

©2019 ALIGNMT LLC | Alignment Consulting | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account